Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis

Inclusion Criteria: * Adults (\>21-year-old). * Diagnosed by dermatologist as plague-type PsO. * Having moderate to severe plague-type PsO as defined by the following: * Psoriasis Area and Severity Index (PASI) ≥12/72, * And, investigator Global Assessment Score (IGA) ≥3, * And, PsO involving body surface area involvement (BSA) ≥10% * And Candidate for phototherapy and/or systemic therapy * Topical corticosteroid up to moderate potencies are allowed * Able to provide informed consent. Exclusion Criteria: * Forms of PsO other than plaque-type. * Evidence of skin conditions at the time of the screening visit (e.g. eczema) that would interfere with evaluation of the effect of the investigational product on PsO. * Evidence of active tuberculosis or other active infections (like Hepatitis C/B), malignancy; active or known use of other immunosuppressive drugs (eg. AIDS, rheumatoid arthritis, organ rejection etc) at the screening visit. * Previous exposure to any systemic immunosuppressants (eg. methotrexate) or phototherapy * History or current signs of a severe, progressive, or uncontrolled renal, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances. * Having current or history of malignancy, except non-melanoma skin cancer, within the previous 5 years that have been adequately treated. * History of inflammatory bowel disease. * Pregnancy or lactating mothers. * As treatment regimen is different, participants with evidence of PsA will be excluded